




ADVERTISING 2019

US-China Biomedical Technology Inc.
Rank 27 of 28





RealRate

ADVERTISING 2019

US-China Biomedical Technology Inc. Rank 27 of 28

The relative strengths and weaknesses of US-China Biomedical Technology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of US-China Biomedical Technology Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 3,365% points. The greatest weakness of US-China Biomedical Technology Inc. is the variable Other Net Income, reducing the Economic Capital Ratio by 1,364% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,804%, being 1,492% points below the market average of -312%.

Input Variable	Value in 1000 USD
Assets, Current	61
Assets, Non-Current	0
Cost of Goods and Services Sold	0
General and Administrative Expense	0
Intangible Assets	0
Liabilities, Current	18
Liabilities, Non-Current	0
Marketing and Selling Expenses	0
Other Assets	19
Other Compr. Net Income	0
Other Expenses	0.91
Other Liabilities	334
Other Net Income	-481
Other Revenues	0
Property, Plant and Equipment	0

Output Variable	Value in 1000 USD
Assets	81
Liabilities	352
Expenses	0.91
Revenues	0
Stockholders Equity	-272
Net Income	-482
Comprehensive Net Income	-482
Economic Capital Ratio	-1,804%